Search Results

AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the closing of a $33.6 million Series C-1 Preferred Stock financing.

AZTherapies, Inc., a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the completion of the last patient/last visit in its COGNITE Phase 3 clinical trial, which is evaluating the safety and efficacy of ALZT-OP1,

Noah Gottdiener of Duff & Phelps and Thierry Porté of J.C. Flowers & Co. join BOD Retired Eli Lilly executive Joseph B. Kelley joins Business Advisory Board BOSTON, July 22, 2020 (GLOBE NEWSWIRE) -- AZTherapies, Inc. , a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the appointment of three prominent business leaders to its Board of Directors and Business Advisory Board: Noah Gottdiener, Chief Executive Officer an

AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the acquisition of Smith Therapeutics, a private biopharmaceutical company with a shared goal of targeting neuroinflammation to treat neurodegenerative disease.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027

The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate ALZT-OP1 for the treatment of early Alzheimer’s disease and its pipeline of candidates targeting neuroinflammation to treat neurodegenerative diseases.